20231022-浙商证券-医药生物周跟踪_药店纳入医保门诊统筹_连锁药店行业变化_17页_1mb

报告摘要

Summary of Pharmaceutical Industry Weekly Report (October 22, 2023)

Investment Outlook

Pharmacy Insurance Policies: The inclusion of drugstores in employee医保门诊统筹 has increased payment volumes for chain drugstores. Policies like医保共济机制 and定点零售药店 management requirements favor large chains, boosting their market share and industry concentration. Head companies are expanding rapidly through store openings and franchise growth, with examples like Yifeng and Dashilin reporting significant net store increases.
Expansion Cycle: The sector is entering an acceleration phase due to policy benefits and post-pandemic recovery, with strategies focusing on low-capital expansion like franchising.

Market Performance

Overall Decline: The pharmaceutical sector fell by 6.88% week-over-week, outperforming the negative trend with a cumulative loss of 11.5% in 2023 compared to the沪深300 index. Valuation at 25.60x PE is historically low, with an industry premium rate of 142% relative to the index.
Sub-sectors: High volatility; services and chemical products were relatively stable, while materia medica and medical devices saw large drops. Trading volume increased to 94% of the A-share market, above historical averages.
Haitong Holdings: Net outflows of 1.51 billion yuan for the industry, with all sub-sectors experiencing declines in foreign investment.

recommendations

Focus Areas: Emphasize traditional Chinese medicine (e.g., Kan'enbei, Kangyuan Yeya), innovative drug manufacturing (e.g.,药明康德,联影医疗), and biologics. Key companies recommended include康恩贝, 济川药业, and others in the CXO supply chain.
Annual Strategy: Capitalize on the 2023 recovery cycle with themes like demand rebound, policy optimization, and product innovation. Sectors like APIs, controlled substance chain, and medical devices are key.

Risk Assessment

Potential Dangers: Policy shifts (e.g., healthcare reforms), R&D delays, and missed earnings forecasts could adversely affect the sector. Supply chain disruptions or regulatory changes are additional concerns.

For detailed data on holdings and valuation, refer to the full report. This summary excludes specific stock predictions and risk factors outlined in the source.

展开完整摘要